Illustration of antibodies binding a cell surface in emerald green

What Is an FDA Complete Response Letter? CRLs Explained

Table of Contents

An FDA complete response letter means a drug or biologic will not be approved as submitted. What a CRL must contain, the sponsor’s options and the clocks.

Last updated: November 15, 2026

A complete response letter (CRL) is FDA’s formal notice that it will not approve a drug or biologic application in its present form. It lists every deficiency the review found. The sponsor then resubmits, withdraws or, for drugs, requests a hearing, with a one year clock to act.

Scope: US marketing applications for drugs (NDAs) and biologics (BLAs) under 21 CFR 314.110 and 601.3, plus FDA’s newer practice of publishing CRLs. Medical devices use a different system, covered in our PMA not approvable letter guide.

What is a complete response letter from FDA?

A CRL is the letter FDA sends at the end of a review cycle when it decides it will not approve the application in its present form. It is not a permanent rejection. The application stays open, and the letter tells the sponsor what stands between it and approval.

The rule for drugs sits at 21 CFR 314.110 and the parallel rule for biologics at 21 CFR 601.3. Both were published in the Federal Register on July 10, 2008 (73 FR 39609 and 39611). The drug rule says FDA sends a CRL when it determines it will not approve an application “in its present form.” The biologics rule uses the same phrase for a BLA or supplement.

The CRL arrives on or before the PDUFA goal date, which is why investors and partners treat that date as the binary. Our PDUFA date explainer covers how that date is set and when it moves.

What does a CRL have to include?

Under 21 CFR 314.110(a), the letter describes all of the specific deficiencies FDA identified, reflects a complete review of the data submitted, and names any amendments the agency has not yet reviewed. “When possible,” it recommends actions that could make the application approvable. The biologics rule carries the same recommendation language.

Two practical points follow. First, a CRL is supposed to be complete, so a sponsor should not expect a second list of new problems on the next cycle for the same data. Second, the recommendations are not a guarantee. Doing exactly what the letter suggests makes a resubmission reviewable, not automatically approvable.

Neither rule spells out that FDA must say whether a new trial is needed. The regulatory text only requires the deficiencies and, when possible, a path, so when the problem is the evidence itself, read the recommendations closely for whether a new study is implied.

What are the sponsor’s options after a CRL?

The sponsor has three options for a drug and two for a biologic. It can resubmit with fixes, withdraw the application, or (drugs only) request an opportunity for a hearing on whether approval should be refused. Withdrawal is “without prejudice to a subsequent submission,” so the sponsor can file again later.

Option Drugs (NDA, 314.110) Biologics (BLA, 601.3) What happens next
Resubmit Yes, as Class 1 or Class 2 Yes New review cycle starts on the date FDA receives the resubmission
Withdraw Yes, without prejudice Yes Application closes; a new filing can come later
Request a hearing Yes, to CDER’s Associate Director for Policy Not listed in 601.3 FDA responds within 60 days of the request
Do nothing for 1 year FDA may treat it as a request to withdraw Same Written notice, then 30 days to respond before the application is deemed withdrawn

Source: 21 CFR 314.110 and 601.3 (2024 edition). Table compiled by BioMed Nexus.

How long does a sponsor have to respond to a CRL?

One year. Under 314.110(c) and 601.3(c), FDA may treat a failure to resubmit, withdraw or (for drugs) request a hearing within one year of the letter as a request to withdraw. The sponsor can ask for more time, and the rule says FDA “will grant any reasonable request” for an extension.

If the year passes with no action and no extension, FDA sends written notice. The sponsor then has 30 days to explain why the application should stay open and to ask for more time. With no reply, the application is deemed withdrawn. For programs that need a new trial, the extension request is routine housekeeping, but it has to be made.

What is the difference between a Class 1 and Class 2 resubmission?

The class sets the length of the next review. Under 314.110(b)(1), a Class 1 resubmission starts a new two month review cycle and a Class 2 resubmission starts a new six month cycle, both counted from the date FDA receives it. The PDUFA VII commitment letter uses the same two and six month goals.

Our read: Class 1 fits narrow items. Anything that brings new clinical data, a new analysis FDA has to evaluate in depth, or manufacturing fixes that need inspection generally lands in Class 2. FDA classifies the resubmission when it arrives, so sponsors should not model a two month cycle unless the fix is plainly minor.

Does FDA publish complete response letters now?

Yes. On July 10, 2025, FDA published more than 200 CRLs tied to applications submitted from 2020 to 2024 that were later approved, redacted for trade secrets and confidential commercial information. On September 4, 2025, it posted 89 previously unpublished CRLs issued from 2024 onward for pending or withdrawn applications and said it “will release future complete response letters (CRLs) promptly after they are issued to sponsors.”

The letters sit in a centralized openFDA dataset and, per FDA, contain company names while removing confidential commercial information, trade secrets and personal information. FDA’s July 2025 release cited a 2015 FDA analysis finding that company announcements of non approvals omitted 85% of the agency’s safety and efficacy concerns.

That changes the disclosure math. A law firm advisory from Debevoise and Plimpton dated April 29, 2026 told companies to assume CRLs will be made public and to draft press releases, SEC filings and risk factors with that in mind. The same advisory noted an April 20, 2026 citizen petition from an unnamed company asking FDA for advance notice and a chance to propose redactions before publication.

What kinds of problems lead to a CRL?

Most letters fall into a few buckets: the efficacy evidence is not sufficient, the safety profile does not support the benefit, manufacturing or facility problems, or labeling and data issues that cannot be solved inside the review clock. The bucket matters more than the letter itself, because it decides the fix and the timeline.

The clearest example this month is Summit Therapeutics. On November 15, 2026, Summit disclosed a CRL for ivonescimab in EGFR mutated lung cancer. Per Summit, FDA said substantial evidence of effectiveness was not established without a statistically significant overall survival improvement, and that a progression free survival benefit alone did not support a positive benefit risk profile. That is an evidence problem, the hardest bucket to fix quickly. Our full story: FDA rejects ivonescimab over missing overall survival win.

Deficiency type Typical fix Likely resubmission class Rough time to refile (our judgment)
Labeling or minor data clarifications Revised label, responses to questions Class 1 possible Weeks
Manufacturing or facility (CMC, inspection) Remediation, reinspection Class 2 Months, set by the site
Safety database too small or a signal More exposure data, risk management plan Class 2 Months to years
Efficacy evidence not sufficient New analysis FDA accepts, or a new trial Class 2 Often years if a trial is needed

BioMed Nexus framework. Timelines are editorial judgment, not FDA figures; the class decision belongs to FDA.

How should a company respond to a CRL? Our checklist

This is our framework for executives, regulatory leads and investors reading a fresh CRL.

  1. Sort the deficiencies. Separate evidence, safety, CMC and labeling items. One evidence item outweighs ten labeling items.
  2. Read the recommendations literally. Note whether FDA names a new trial, a new analysis or specific data. Vague recommendations usually mean a meeting is needed.
  3. Request a meeting with FDA early. Use it to confirm what a complete resubmission looks like before committing budget.
  4. Plan the disclosure as if the letter will be public. FDA now publishes CRLs. A press release that understates the letter can be contradicted by the letter itself.
  5. Calendar the one year clock. File an extension request if the fix needs more than a year.
  6. Model the class honestly. Assume a six month Class 2 review unless the fix is clearly narrow.
  7. Check ex US filings. Other regulators make independent decisions, and a US CRL can still shape their questions.
  8. Revisit partner and financing terms. Milestones, royalties and CVRs tied to US approval dates may need to be reset.

How is a CRL different from other FDA actions?

A CRL comes at the end of a full review. A refuse to file decision comes at the front, within the 60 day filing window, when the application is not complete enough to review. A clinical hold stops a trial under an IND and is not a marketing decision at all. Devices get a different set of letters, including the PMA not approvable letter.

Approval can also come with strings. Accelerated approval requires confirmatory trials, covered in our accelerated approval guide, and labels can carry boxed warnings, covered in our boxed warning explainer.

What to watch next

  • Whether the Summit ivonescimab letter appears in FDA’s openFDA CRL dataset, and how closely it matches the company’s summary.
  • Any FDA statement on publication timing, given the April 2026 citizen petition asking for advance notice.
  • Whether more oncology CRLs cite the absence of a statistically significant overall survival result where survival was a primary endpoint.
  • PDUFA VIII negotiations, which could reshape review and meeting commitments after the current agreement.

FAQ

Is a complete response letter a rejection?

It is a decision not to approve the application in its present form. The application stays open, and the sponsor can resubmit after fixing the deficiencies the letter lists.

What law governs CRLs?

21 CFR 314.110 covers drug applications and 21 CFR 601.3 covers biologics license applications. Both were published in the Federal Register on July 10, 2008.

Does a CRL list every problem FDA found?

The drug rule says the letter describes all of the specific deficiencies FDA identified and reflects a complete review of the data submitted, while naming any amendments not yet reviewed.

How long does a company have to respond?

One year from the letter. FDA may treat inaction after that as a request to withdraw, unless the sponsor asked for an extension, which FDA says it will grant if reasonable.

How long does FDA take to review a resubmission?

Two months for a Class 1 resubmission and six months for a Class 2 resubmission, counted from the date FDA receives it.

Can a sponsor appeal a CRL?

For drugs, 314.110 lets the applicant request an opportunity for a hearing, and FDA responds within 60 days. The biologics rule lists only resubmission and withdrawal.

Are CRLs public?

Increasingly, yes. FDA published more than 200 letters in July 2025, 89 more in September 2025, and said it will release future CRLs promptly after issuance, redacted for confidential information but with company names.

Why did FDA start publishing CRLs?

FDA cited a 2015 agency analysis finding that company announcements of non approvals omitted 85% of FDA’s safety and efficacy concerns, and framed publication as transparency for patients, investors and developers.

Can a drug be approved after a CRL?

Yes. FDA’s first published batch in July 2025 was made up of letters for applications that were later approved, which shows a CRL is often a delay rather than an end point.

Does a CRL affect approvals outside the US?

Not directly. Other regulators decide independently, though a US letter can shape the questions they ask and the timing of filings.

What is the difference between a CRL and a refuse to file letter?

A refuse to file decision comes within the 60 day filing period when an application is too incomplete to review. A CRL comes after a full review.

Sources

  • 21 CFR 314.110, Complete response letter to the applicant (govinfo, 2024 edition). Primary.
  • 21 CFR 601.3, Complete response letter to the applicant (govinfo, 2024 edition). Primary.
  • FDA press release, “FDA Embraces Radical Transparency by Publishing Complete Response Letters,” July 10, 2025. Primary.
  • FDA press release, “FDA Announces Real Time Release of Complete Response Letters, Posts Previously Unpublished Batch of 89,” September 4, 2025. Primary.
  • FDA PDUFA VII commitment letter (resubmission goals). Primary.
  • Summit Therapeutics press release, “Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application,” November 15, 2026. Primary (company).
  • Debevoise and Plimpton, “FDA’s Real Time Release of Complete Response Letters,” April 29, 2026. Attributed.

Related coverage

Get the daily briefing on FDA decisions and industry moves: subscribe to BioMed Nexus.

Featured Articles

Join 65,000+ Biotech, MedTech, and Pharma Leaders

Your Daily Edge in Biotech, MedTech, and Pharma

Get trusted, high-signal updates every morning
Breakthroughs, trial data, deals, and the news that matters